# U.S. Renal Care

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/u-s-renal-care

- Industry: Healthcare
- Headquarters: Plano, US
- Website: www.usrenalcare.com
- Total disclosed funding: $48M
- Latest round: Series C (Jul 10, 2006)
- Investors on record: 4

## About

U.S. Renal Care, Inc. is a leading provider of kidney care solutions across the United States, specializing in dialysis treatments tailored to meet the diverse needs of patients with kidney disease.U.S. Renal Care, Inc. offers kidney care services with a focus on dialysis and care management. Founded in 2000, the company is headquartered in Plano, US. In February 2019, Bain Capital, Revelstoke Capital Partners, and Summit Partners acquired U.S. Renal Care from several investors. The company has undergone significant changes in management ownership without mentioning any subsidiaries. Mark Caputo serves as CEO, leading the company to enhance its healthcare service offerings.U.S. Renal Care specializes in comprehensive kidney care solutions, including a range of dialysis treatment options designed to accommodate the diverse needs and lifestyles of patients with kidney disease. The company collaborates with leading nephrologists across 32 states in the U.S. to provide personalized care before, during, and after dialysis treatment, ensuring a supportive environment for over 36,000 patients. Their services focus on not only the clinical aspects of kidney care but also encompass diet and nutrition, exercise and fitness, and emotional health, creating a holistic approach to wellness for individuals facing renal challenges. U.S. Renal Care emphasizes educational resources for new patients to ease their transition into treatment, reflecting their commitment to improving patient outcomes. The geographical markets served include major metropolitan areas and rural regions across the United States, where the company seeks to enhance access to renal care for its diverse clientele.U.S. Renal Care operates within a structured revenue model primarily based on the provision of dialysis services and care management for patients with kidney disease. The company's transactions typically involve direct delivery of healthcare services to patients, supported by partnerships with nephrologists and health systems. Revenue generation occurs through reimbursements from government and private insurance providers for the treatment services rendered, which may include inpatient and outpatient dialysis sessions, as well as ancillary services like nutritional counseling and social work support. The company’s offerings focus on creating value through high-quality patient care, and their business structure facilitates direct relationships with both healthcare providers and patients, ensuring a streamlined service delivery model. U.S. Renal Care has been recognized for its commitment to clinical excellence and operational efficiency, establishing itself as a key player in the kidney care market.U.S. Renal Care intends to utilize the proceeds from its recent Recapitalisation round, completed in February 2019, where it raised USD 137.50 mn, to enhance its service offerings and expand into additional markets. The company is looking to develop new kidney care products that will launch in the upcoming years, aiming to diversify its service portfolio. Additionally, U.S. Renal Care is targeting expansion into new geographic regions to improve access to its services. Specific markets for this expansion will be identified as the company solidifies its strategic growth plans throughout 2024.

## Funding rounds

- Series C, Jul 10, 2006, $36M — Thoma Bravo
- Series B, Mar 31, 2005, $12M — Salix Ventures, SV Health Investors, Select Capital Ventures

## Investors

- Salix Ventures (https://capitalatlas.ai/funds/salix-ventures) — Series B
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series B
- Select Capital Ventures (https://capitalatlas.ai/funds/select-capital-ventures) — Series B
- Thoma Bravo (https://capitalatlas.ai/funds/thoma-bravo) — Series C